Dewa Putu Gede Purwa SAMATRA, Eric Hartono TEDYANTO, Anak Agung Ayu Putri LAKSMIDEWI, I Made Oka ADNYANA, I Putu Eka WIDYADHARMA

Prolonged use of statins and peripheral neuropathy:A systematic review

Peripheral neuropathy is one of the most common neurological disorder. Traditionally, diabetes mellitus is the most common aetiology of peripheral neuropathy. However, there are many other aetiologies of peripheral neuropathy, such as drug-induced, spinal trauma, alcoholism, vitamin B12 deficiency, and many more. In previous studies, long-term statin use was also associated with peripheral neuropathy.We conducted a systematic search through PubMed and Embase using the protocol following the PRISMA statement in making a systematic review. W e included article that published in the last 10 years (from 2011 until July 2020). Two reviewers extracted data from the articles that have been selected. We extracted the study population, study design, type of intervention, control variable, p-value, and the outcome of the studyWe found 250 journals in our search strategy, and at the end, 4 journals included. Some studies revealed that peripheral neuropathy was observed during the long-term treatment of statin. However, some studies also revealed that statin does not increase the risk of peripheral neuropathy. The possible mechanism of statin-induced peripheral neuropathy in humans are disturbing the function and integrity of cell membrane, the role of alfa-tocopherol or Vitamin E, and the role of ubiquinone (Coenzyme Q10). In contrast, it is believed that statins lowering the risk of peripheral neuropathy through the anti-inflammatory effects of statins. Different result from each study can be caused by various factors. Besides the peripheral neuropathy side effect that described in the literature, statins are well tolerated. Awareness the side effects would lead to better treatment. Future study about association between statins and peripheral neuropathy is needed.

PDF

___

1. Mohamed A Hammad, Syed Azhar Syed Sulaiman, Saleh Alghamdi, et al. Statins-related Peripheral Neuropathy Among Diabetic Patients. Diabetes & Metabolic Syndrome: Clinical Research and Reviews. Elsevier,2020;14:341-6.
2. St Charles JL, Bell JA, Gadsden BJ, et al. Guillain Barré Syndrome is induced in Non-Obese Diabetic (NOD) mice following Campylobacter jejuni infection and is exacerbated by antibiotics. J Autoimmun 2017;77:11- 38.
3. West B. The implications of statin induced peripheral neuropathy. J Foot Ankle Res 2011;4:57.
4. Emad M, Arjmand H, Farpour HR, Kardeh B. Lipidlowering drugs (statins) and peripheral neuropathy. Electron Physician 2018;10:6527-33.
5. de Langen JJ, van Puijenbroek EP. HMG-CoAreductase inhibitors and neuropathy: Reports to the Netherlands Pharmacovigilance Centre. Neth J Med 2006;64:334-8.
6. McCarberg B, D’Arcy Y, Parsons B, et al. Neuropathic pain: a narrative review of etiology, assessment, diagnosis, and treatment for primary care providers. Current Medical Research and Opinion. 2017;33:1361- 9.
7. Svendsen T de K, Nørregaard Hansen P, García Rodríguez LA, et al. Statins and polyneuropathy revisited: case-control study in Denmark, 1999–2013. Br J Clin Pharmacol 2017;83:2087-95.
8. Bosomworth NJ. Statin therapy as primary prevention in exercising adults: Best evidence for avoiding Myalgia. J Am Board Fam Med 2016;29:727-40.
9. Ozdemir IH, Copkiran O, Tikiz H, et al. Peripheral polyneuropathy in patients receiving long-term statin therapy. Turk Kardiyol Dern Ars 2019;47:554-63.
10. Apostolopoulou M, Corsini A, Roden M. The role of mitochondria in statin-induced myopathy. Eur J Clin Invest 2015;45:745-54.
11. Otruba P, Kanovsky P, Hlustik P. Treatment with statins and peripheral neuropathy: Results of 36-months a prospective clinical and neurophysiological followup. Neuroendocrinol Lett 2011;32:688-90.
12. Warendorf JK, Vrancken AFJE, Van Eijk RPA, et al. Statins do not increase risk of polyneuropathy A case-control study and literature review. Neurology. 2019;92:2136-44.
13. Golomb BA, Evans MA. Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. American Journal of Cardiovascular Drugs 2008;8:373-418.
14. Muller DPR. Vitamin E and neurological function. Molecular Nutrition and Food Research 2010;62:107- 12.
15. Rajabally YA. Neuropathy and impaired glucose tolerance: An updated review of the evidence. Acta Neurologica Scandinavica 2011;124:1-8.
16. Vincent AM, Hinder LM, Pop-Busui R, et al. Hyperlipidemia: A new therapeutic target for diabetic neuropathy. Journal of the Peripheral Nervous System. 2009;14:257-67.
17. Gustavsson C, Agardh CD, Zetterqvist A V., et al. Vascular cellular adhesion molecule-1 (VCAM-1) expression in mice retinal vessels is affected by both hyperglycemia and hyperlipidemia. PLoS One. 2010; 5:12699.
18. Visser NA, Vrancken AFJE, Van Der Schouw YT, et al. Chronic idiopathic axonal polyneuropathy is associated with the metabolic syndrome. Diabetes Care 2013;36:817-22.